Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Epizyme, GSK Form Epigenetic Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Epizyme, GSK Form Epigenetic Alliance

novel small molecule therapeutics targeting histone methyltransferases (HMTs), an important class of epigenetic enzymes, for the treatment of cancer and other diseases.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Epizyme and GlaxoSmithKline have entered a strategic alliance to develop novel small molecule therapeutics targeting histone methyltransferases (HMTs), an important class of epigenetic enzymes, for the treatment of cancer and other diseases.

Epizyme will use its HMT discovery platform, chemical library, and expertise to discover and develop HMT therapeutics against the set of targets to be included in the collaboration. Epizyme will receive an upfront payment of $20 million, as well as research funding. Epizyme is eligible to receive more than $630 million in total milestone payments if products for all targets in the collaboration are commercialized, as well as royalties on sales. Epizyme will be primarily responsible for research up to development candidate selection, and GSK will be responsible for development and commercialization.

Robert Gould, Ph.D., chief executive officer and president of Epizyme, said, “Epizyme’s mission is to develop personalized therapeutics for genetically-defined patients based on our understanding of the driving role played by many HMTs in human disease. We are excited to be working with GSK. This collaboration validates our unique discovery platform and the targeted approach we bring to HMT therapeutics.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters